Sitemap

Pages

• Home
• Funding
  • Rare disease research funding
    • Philanthropic Fund
      • The LifeArc Philanthropic Fund
      • Funded projects
      • Panel members
      • Frequently asked questions
      • Contact the Philanthropic Fund
    • LifeArc & Action Medical Research Fund
    • LifeArc & GOSH Charity Fund
    • Motor Neurone Disease Translational Research Fund
    • LifeArc-CSO Fund for Scottish Translational Researchers
  • Seed Fund
  • Development Gap Fund
• About us
  • Who we are
  • Governance and structure
    • Our Management Team
    • Articles of Association
    • Strategic Advisory Council 
    • Our Trustees
    • Bribery and Corruption statement
    • Safeguarding Policy
    • Modern slavery statement
    • LifeArc’s UK tax strategy
  • Our people
  • Our impact
• Working with us
  • Support for MRC researchers
  • Helping charities
  • Our partners
  • Advise & Connect: COVID-19
    • About Advise & Connect
    • How to apply
    • FAQs
    • Apply now
    • Contact the Advise & Connect team
  • Licensing opportunities
  • Submit your idea
• Capabilities
  • Capabilities overview
  • Drug discovery
    • Drug discovery FAQs
  • Antibody engineering
  • IP management and technology transfer
  • Diagnostics development
    • About diagnostics development
    • Diagnostics FAQs
    • Diagnostic application
• Careers
  • Jobs
  • Industrial placements
  • Fellowships
    • Overview of LifeArc Fellowships
    • LifeArc-AUTM technology transfer career training fellowships
      • 2019-2020 Fellows
      • 2018-2019 Fellows
      • 2017-2018 Fellows
        • Dr Sara Garcia Gómes
        • Dr Sven Hofmann
        • Dr Tim Shuttleworth
        • Dr Gaganmeet Singh
        • Dr Gen Tamjar
    • The Technology Transfer Fellows Programme
      • Technology Transfer Alumni
      • Dr Elliott Jennings
      • Dr Joo-Hee Sir
      • Dr Diana Alexieva
• News
  • Latest news
  • Case studies
  • Reports and publications
    • Annual Report and Accounts 2020
  • COVID-19 Information
    • Coronavirus (COVID-19) therapeutics: £10 million call for rapid deployment
      • Almitrine
      • ATTACC
      • ATTRACT
      • DEFEAT-COVID study
      • FaST for COVID
      • FLARE Trial
      • IONIC Trial
      • PIONEER Trial
      • PROTECT-V
      • RUX-COVID
      • RAVEN
      • SFX-01
      • SPIKE-1 Trial
      • The COVASE study
  • Media contacts
• Workplace risk assessment
• Contact us
• Pharma/Biotech
• Research Organisation
• Medical Charity
• Cookie policy
• Privacy policy
• Academic Scientist
• Contact the LifeArc & MND Association Fund